CD151 interacts with integrin beta 2 in B cell lymphomas
Authors:
- Philipp M. HagemannPHPhilipp M. Hagemann
- Angelique N. KenyonAKAngelique N. Kenyon
- Alfredo Cabrera-OreficeACAlfredo Cabrera-Orefice
- Abbey B. ArpAAAbbey B. Arp
- Eva A. M. HesiusEHEva A. M. Hesius
- Michiel van Den BrandMBMichiel van Den Brand
- Sjoerd J. van DeventerSDSjoerd J. van Deventer
- Daphne de JongDJDaphne de Jong
- Blanca ScheijenBSBlanca Scheijen
- Zijun Y. Xu-MonetteZijun Y. Xu-Monette
- Ulrich BrandtUBUlrich Brandt
- Cornelia G. SpruijtCSCornelia G. Spruijt
Open Access
- 4 June 2025
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 82 (1) , 1-14
Abstract
CD151 is a broadly expressed four-transmembrane protein (tetraspanin) that interacts with laminin‐binding integrins like integrin alpha 3 (ITGA3). CD151 drives tumor development and expression correlates with poor prognosis in solid cancers, but CD151 has not been studied in B cell malignancies. We investigated CD151 expression on normal human B cells and B cell lymphomas using highly sensitive flow cytometry and immunohistochemistry. Expression of CD151 increased during B cell differentiation from naïve to memory B cells to plasma cells. B lymphoma cell lines and human lymphoma biopsy samples expressed higher levels of CD151 compared to normal B cells, but CD151‐deficient lymphomas were identified as well. To investigate the function of CD151 in B cells, CD151‐deficient and stably transduced CD151 expressing B lymphoma cell lines were generated. Immunoprecipitation-mass spectrometry analysis of CD151 protein complexes identified integrin beta 2 (ITGB2) as new interaction partner in lymphoma cells. Deficiency of CD151 decreased cell surface expression of alpha integrin subunits L (ITGAL) and M (ITGAM), and impaired ICAM-1-mediated cell spreading. Interestingly, B cells and lymphomas did not express ITGA3‐bound CD151 compared to T cells that expressed two different populations of integrin‐bound and integrin‐free CD151. Despite CD151 expression not being related to clinical outcome of patients with diffuse large B cell lymphoma (DLBCL), CD151 expression was predominantly detected in the activated (ABC) subset of DLBCL. Taken together, we identified a new molecular association of CD151 with ITGB2, and targeting integrin-free CD151 in DLBCL may represent a new target for immunotherapy.Keywords
Funding Information
- ZonMw (09120012010023)
- KWF Kankerbestrijding (12949, 14726)
- H2020 European Research Council (724281)
- European Research Council (101112687)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Gravitation programme IMAGINE! (project number 24.005.009, the Institute of Chemical Immunology (project ICI 000-23))
This publication has 60 references indexed in Scilit:
- Basement membrane defects in CD151-associated glomerular diseasePediatric Nephrology, 2022
- Key Role of CD151-integrin Complex in Lung Cancer Metastasis and Mechanisms InvolvedCurrent Medical Science, 2020
- Novel Insights into Membrane Targeting of B Cell LymphomaTrends in Cancer, 2017
- Tetraspanins CD9 and CD151 at the immune synapse support T‐cell integrin signalingEuropean Journal of Immunology, 2014
- CD151 in cancer progression and metastasis: a complex scenarioLaboratory Investigation, 2014
- Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancerBritish Journal of Cancer, 2011
- Expression and Prognostic Significance of CD151, c-Met, and Integrin alpha3/alpha6 in Pancreatic Ductal AdenocarcinomaDigestive Diseases and Sciences, 2010
- The Inhibition of Tumor Cell Intravasation and Subsequent Metastasis via Regulation of In Vivo Tumor Cell Motility by the Tetraspanin CD151Cancer Cell, 2008
- LFA-1/ICAM-1 Interaction Lowers the Threshold of B Cell Activation by Facilitating B Cell Adhesion and Synapse FormationImmunity, 2004
- Tetraspanins: molecular organisers of the leukocyte surfaceTrends in Immunology, 2003